Navigation Links
Vascular Designs, Inc. Receives CE Mark Approval for Its IsoFlow™ Infusion Catheter to Target Cancerous Tumors
Date:11/14/2011

SAN JOSE, Calif., Nov. 14, 2011 /PRNewswire/ -- Vascular Designs, Inc., a medical device manufacturing company, today announced that its IsoFlow™ Infusion Catheter has received CE Mark approval for use in Europe and Canada. The IsoFlow™ Infusion Catheter enables targeted sideways perfusion, allowing physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With IsoFlow™ Infusion Catheter's unique design, medications can be delivered into areas that could not previously be treated directly, for instance, a cancerous tumor. The device also facilitates the LACE™ (Lateral Arterial Chemo Embolization) procedure.

(Logo: http://photos.prnewswire.com/prnh/20111114/SF06426LOGO)

"CE Mark approval is an important confirmation of the substantial benefits that patients will receive from targeted treatment of cancerous tumors," said Robert Goldman, CEO of Vascular Designs, Inc. and creator of the IsoFlow Infusion Catheter. "Directing treatment to specific locations increases the number of treatment options allowing better access to tumors and may reduce the discomfort to patients associated with the systemic application of chemotherapy."

About Vascular Designs, Inc.

Vascular Designs, Inc. is a medical device company located in San Jose, California. Founder Robert Goldman developed the idea behind Vascular Designs and its innovative IsoFlow™ Infusion Catheter. His personal experience of watching loved ones suffer from, and succumb to cancer, had a profound influence on the creation of IsoFlow.

With the IsoFlow Infusion Catheter's unique design, medications can be pushed into areas that could not previously be treated directly. According to numerous studies, this type of approach to delivery can increase drug concentrations at targeted sites while reducing systemic exposure, potentially improving treatment outcomes.

The IsoFlow Infusion Catheter is in use in hospitals throughout the United States.

For more information on Vascular Designs, Inc., please visit www.vasculardesigns.com.

To view an animation illustrating the IsoFlow Infusion Catheter in action and other press materials, please visit http://www.vasculardesigns.com/news.htm.

Media Contact: Dan Orloff, Orloff Williams Partners, San Jose, 408-202-3188, dorloff@orloffwilliams.com


'/>"/>
SOURCE Vascular Designs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
2. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
3. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
4. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
5. Cardiologists Tackle Next Frontier in Cardiovascular Disease
6. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
7. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
8. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
Breaking Medicine News(10 mins):